Mitochondrial Medicine pp 113-122 | Cite as
Ex Vivo Generation of Functional Immune Cells by Mitochondria-Targeted Photosensitization of Cancer Cells
Abstract
Stimulating the immune system for potent immune therapy against cancer is potentially a revolutionary method to eradicate cancer. Tumors stimulated with photosensitizers (PSs) not only kill cancer cells but also help to boost the immune system. We recently reported that tumor-associated antigens (TAAs) generated by delivery of a mitochondria-acting PS zinc phthalocyanine (ZnPc) to MCF-7 breast cancer cells followed by laser irradiation can lead to ex vivo stimulation of mouse bone marrow-derived dendritic cells (BMDCs). The antigens generated from the breast cancer cells were also found to cause significant DC maturation and the activated DCs were able to stimulate T cells to cytotoxic CD8+ T cells. In this protocol, we describe methods to engineer a mitochondria-targeted biodegradable nanoparticle (NP) formulation, T-ZnPc-NPs for delivery of ZnPc to the mitochondria of MCF-7 cells, subsequent photodynamic therapy (PDT) using a long wavelength laser irradiation to produce TAAs, DC stimulation by the TAAs to secrete interferon-gamma (IFN-γ), and matured DC-driven T-cell activation.
Key words
Photodynamic therapy Tumor antigen Mitochondria Biodegradable nanoparticleReferences
- 1.Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208:495–506CrossRefPubMedGoogle Scholar
- 2.Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H et al (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133:799–804CrossRefPubMedGoogle Scholar
- 3.Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRefPubMedGoogle Scholar
- 4.Nguyen PL, Taghian AG, Katz MS, Niemierko A, Raad RFA, Boon WL et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMedGoogle Scholar
- 5.Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489CrossRefPubMedCentralPubMedGoogle Scholar
- 6.Marrache S, Choi JH, Tundup S, Zaver D, Harn DA, Dhar S (2013) Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr Biol 5:215–223CrossRefGoogle Scholar
- 7.Farokhzad OC, Jon SY, Khademhosseini A, Tran TNT, LaVan DA, Langer R (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64:7668–7672CrossRefPubMedGoogle Scholar
- 8.Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103:6315–6320CrossRefPubMedCentralPubMedGoogle Scholar
- 9.Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1–20CrossRefPubMedGoogle Scholar
- 10.Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF et al (2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 105:2586–2591CrossRefPubMedCentralPubMedGoogle Scholar
- 11.Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 108:1850–1855CrossRefPubMedCentralPubMedGoogle Scholar
- 12.Marrache S, Dhar S (2013) Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci U S A 110:9445–9450CrossRefPubMedCentralPubMedGoogle Scholar
- 13.Marrache S, Pathak RK, Darley KL, Zaver D, Choi JH, Kolishetti N et al (2013) Nanocarriers as therapeutic platforms for tracking and treating diseases. Curr Med Chem 20:3500–3514CrossRefPubMedGoogle Scholar
- 14.Smith RAJ, Porteous CM, Gane AM, Murphy MP (2003) Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A 100:5407–5412CrossRefPubMedCentralPubMedGoogle Scholar
- 15.Marrache S, Dhar S (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A 109:16288–16293CrossRefPubMedCentralPubMedGoogle Scholar
- 16.Marrache S, Tundup S, Harn DA, Dhar S (2013) Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano 7:7392–7402CrossRefPubMedGoogle Scholar
- 17.Powell T, Major JR, Macpherson G (2001) Generation of dendritic cells from rat bone marrow. Methods Mol Med 64:199–205PubMedGoogle Scholar